SUVEN LIFE SCIENCES LTD·PHARMACEUTICALS 70.24·Healthcare Services Companies

2026-08-21 NSE BSE Web 20%L-ASM-I

Price

373.15

-0.13%
O:377
H:389.9
L:361.4
C:373.15

52W Range

124.11389.9
+201%/-4%

Market Cap

₹9,840.73 Cr

Traded: ₹69.64 Cr (0.71%) 0.0x

Free Float: ₹3,082.12 Cr (2.26% of FF traded)

Volume · 60D trend

18.53 L 0.0x

Delivery: % 0.0x

View Delivery Data

Returns

1W:+0% 1M:+22% 3M:+39% 6M:+90% 12M:+118%

Valuation

P/E--
P/B16.6
P/S984.1
EV/EBIT-18.5

Business Strength

ROE-84.6%
ROCE-84.4%
OPM-4057.1%
NPM-3942.9%

Growth (3Y CAGR)

EPS-42.2%
Sales-19.0%
Profit--
3Y Return+72.0%

Balance Sheet

Debt/Equity0.0
Debt0.01 Cr
Pledge0.0%
CWIP/Fixed Asset5.5%

Cash Position

CFO/NP108.7%
FCF-305 Cr
FCF 3Y Avg-611 Cr
Cash/MCap2.0%

Others

Div Yield0.0%
Div Payout0.0%
Cash Conv. Cycle78 days
Tradeable Free Float31.3%

MTF Exposure Trend

60 sessions · funded amount, % of FF, daily delta

Current
₹ 61.71 Cr
2.00% FF
60d high
₹ 67.29 Cr
60d low
₹ 30.55 Cr
60d mean
₹ 55.25 Cr
vs mean
▲ 11.71%

Growth Trends

Metric10Y5Y3Y1YTTMTrend
ROE
-24.0%
-68.0%
-66.0%
--
--
Stable
Return
+38.0%
+32.0%
+72.0%
+25.0%
--
Stable
Profit
--
--
--
--
-91.0%
--
Sales
-35.0%
-12.0%
-19.0%
--
+17.0%
Stable

Quarterly Results

Jun 2026

6 Aug
Rev
4 Cr
+100% YoY+100% QoQ
OPM-3711.0%
NPM-3200.0%
PAT
---128 Cr
EPS
-105% YoY-4.8

Mar 2026

13 May
Rev
2 Cr
+100% YoY-33% QoQ
OPM-3331.0%
NPM-2300.0%
PAT
-4% YoY-46 Cr
EPS
+14% YoY-1.7

Dec 2025

29 Jan
Rev
3 Cr
+50% YoY+200% QoQ
OPM-3678.0%
NPM-3400.0%
PAT
-161% YoY-102 Cr
EPS
-150% YoY-4.5

Sep 2025

PDF
Rev
1 Cr
-67% YoY-50% QoQ
OPM-8671.0%
NPM-7700.0%
PAT
-56% YoY-77 Cr
EPS
-49% YoY-3.4

Jun 2025

PDF
Rev
2 Cr
+100% YoY+100% QoQ
OPM-2714.0%
NPM-2600.0%
PAT
-84% YoY-52 Cr
EPS
-83% YoY-2.4

Mar 2025

PDF
Rev
1 Cr
-50% YoY-50% QoQ
OPM-2981.0%
NPM-4400.0%
PAT
-66% YoY-44 Cr
EPS
-65% YoY-2.0

Dec 2024

PDF
Rev
2 Cr
+0% YoY-33% QoQ
OPM-2435.0%
NPM-1950.0%
PAT
+6% YoY-39 Cr
EPS
+6% YoY-1.8

Sep 2024

PDF
Rev
3 Cr
+0% YoY+200% QoQ
OPM-2032.0%
NPM-1666.7%
PAT
-146% YoY-50 Cr
EPS
-293% YoY-2.3

Jun 2024

PDF
Rev
1 Cr
-75% YoY-50% QoQ
OPM-3024.0%
NPM-2800.0%
PAT
-16% YoY-28 Cr
EPS
-17% YoY-1.3

Mar 2024

PDF
Rev
2 Cr
-33% YoY+0% QoQ
OPM-1267.0%
NPM-1350.0%
PAT
+4% YoY-27 Cr
EPS
+4% YoY-1.2

Dec 2023

PDF
Rev
2 Cr
-33% YoY-33% QoQ
OPM-1885.0%
NPM-2100.0%
PAT
+18% YoY-42 Cr
EPS
+18% YoY-1.9

Sep 2023

PDF
Rev
3 Cr
---25% QoQ
OPM-768.0%
NPM-433.3%
PAT
+13% YoY-13 Cr
EPS
---0.6

Jun 2023

PDF
Rev
4 Cr
--+33% QoQ
OPM-737.0%
NPM-600.0%
PAT
-8% YoY-24 Cr
EPS
---1.1

Mar 2023

Rev
3 Cr
--+0% QoQ
OPM-1208.0%
NPM-933.3%
PAT
-33% YoY-28 Cr
EPS
---1.3

Dec 2022

Rev
3 Cr
----
OPM-1719.0%
NPM-1700.0%
PAT
-52% YoY-51 Cr
EPS
---2.3

Revenue & Margin Trends

Annual

Quarterly

Balance Sheet Health

Leverage

Debt / Equity0.03
Interest Coverage-1.2x
Promoter Pledge0.0%
Borrowings17 Cr

Efficiency

Receivable Days78 days
Inventory Days days
Payable Days days
Cash Conversion cycle78 days

Cash Position

Operating Cash Flow-300 Cr
Investing Cash Flow-462 Cr
Financing Cash Flow757 Cr
Free Cash Flow-305 Cr

Detailed Financials

Jun 2026PDF ↗
Mar 2026PDF ↗
Dec 2025PDF ↗
Sep 2025PDF ↗
Jun 2025PDF ↗
Mar 2025PDF ↗
Dec 2024PDF ↗
Sep 2024PDF ↗
Jun 2024PDF ↗
Mar 2024PDF ↗
Dec 2023PDF ↗
Sep 2023PDF ↗
Jun 2023PDF ↗
Mar 2023
Dec 2022
Sales423121231223433
Expenses13652106815345415532334927323455
Operating Profit-132-51-103-80-51-44-39-52-31-30-46-24-28-32-52
OPM %-3711.0%-3331.0%-3678.0%-8671.0%-2714.0%-2981.0%-2435.0%-2032.0%-3024.0%-1267.0%-1885.0%-768.0%-737.0%-1208.0%-1719.0%
Other Income8734112444613662
Interest000000000000000
Depreciation221111211222222
Profit Before Tax-128-46-102-77-52-44-39-50-28-28-42-13-24-28-51
Tax %0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%-4.0%0.0%0.0%0.0%0.0%0.0%
Net Profit-128-46-102-77-52-44-39-50-28-27-42-13-24-28-51
Exceptional Items000000000007000
EPS (Rs)-4.8-1.7-4.5-3.4-2.4-2.0-1.8-2.3-1.3-1.2-1.9-0.6-1.1-1.3-2.3
Sales Growth (YoY)100.0%100.0%50.0%-66.7%100.0%-50.0%0.0%0.0%-75.0%-33.3%-33.3%--------
Sales Growth (QoQ)100.0%-33.3%200.0%-50.0%100.0%-50.0%-33.3%200.0%-50.0%0.0%-33.3%-25.0%33.3%0.0%--
OP Growth (YoY)-158.8%-15.9%-164.1%-53.8%-64.5%-46.7%15.2%-116.7%-10.7%6.3%11.5%--------
OP Growth (QoQ)-158.8%50.5%-28.7%-56.9%-15.9%-12.8%25.0%-67.7%-3.3%34.8%-91.7%14.3%12.5%38.5%--
Profit Growth (YoY)---3.8%-160.5%-55.7%-83.7%-65.6%6.3%-146.5%-16.4%4.0%18.3%13.1%-7.9%-32.9%-52.0%
EPS Growth (YoY)-104.7%13.9%-150.3%-49.1%-83.0%-64.8%6.3%-293.1%-17.3%3.9%18.4%--------
EPS Growth (QoQ)-179.2%61.4%-31.8%-44.1%-17.4%-12.3%21.5%-76.7%-5.7%36.1%-229.3%47.3%13.4%45.7%--
OP Margin-3300.0%-2550.0%-3433.3%-8000.0%-2550.0%-4400.0%-1950.0%-1733.3%-3100.0%-1500.0%-2300.0%-800.0%-700.0%-1066.7%-1733.3%
Net Margin-3200.0%-2300.0%-3400.0%-7700.0%-2600.0%-4400.0%-1950.0%-1666.7%-2800.0%-1350.0%-2100.0%-433.3%-600.0%-933.3%-1700.0%
Material Cost %------------------------------
Employee Cost %204.0%384.0%223.0%661.0%320.0%413.0%302.0%202.0%464.0%145.0%236.0%145.0%139.0%151.0%159.0%
P/S984.071076.48815.20------------------------
P/E------------------------------
P/B16.6514.5720.24------------------------

Shareholding Pattern

Shareholders:66.6K (-15.2%)
Current MixJul 2026

Exchange Filings

50
Company Update11 Aug 2026

Monitoring Agency Report for the quarter ended 30th June, 2026

Company Update07 Aug 2026

Newspaper publication- un-audited finacial results

Result06 Aug 2026

Un-audited Financial results for the quarter ended 30th June, 2026

Board Meeting06 Aug 2026

Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026

Others30 Jul 2026

Annual Report 2025-26 and Notice of 37th Annual General Meeting (AGM) of the Company

Others30 Jul 2026

Business Responsibility and Sustainability Report (BRSR) for FY 2025-26

AGM/EGM30 Jul 2026

Notice of the 37th Annual General Meeting (AGM) of the Company

Insider Trading / SAST20 Jul 2026

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & PACs

Company Update14 Jul 2026

Special window for Re-Lodgment of transfer requests of Physical shares

Company Update14 Jul 2026

Interaction with Investors and Analysts

Company Update10 Jul 2026

Please find enclosed News Release of our company

Company Update08 Jul 2026

Certificate under Reg 74 (5) of SEBI (DP) Regulations, 2018

Company Update08 Jul 2026

Revised outcome of the meeting of Board of Directors - Incorporation of Wholly owned Subsidiary (WOS) in Singapore

Company Update08 Jul 2026

Incorporation of Wholly owned Subsidiary (WOS) in Singapore

Company Update08 Jul 2026

Re-appointment of Dr. Vajja Sambasiva Rao effective from January 21, 2027 for a second term of 5(five) years

Others08 Jul 2026

Outcome of Board Meeting

Company Update08 Jul 2026

Allotment of 18570133 Equity shares of the Company on preferntial basis upon conversion of 18570133 fully paid warrants

Insider Trading / SAST26 Jun 2026

Closure of Trading Window

Company Update22 Jun 2026

Allotment of 2,71,970 Equity shares upon exercise of vested options under SLSL ESOP 2020 Scheme

Company Update22 Jun 2026

Please find enclosed News release of our company

Company Update17 Jun 2026

Please find enclosed News Release of our Company.

Company Update16 Jun 2026

Please find enclosed News Release of our company.

Company Update12 Jun 2026

Please find enclosed News Release of our company.

Company Update29 May 2026

Rectification order for Assesment year 2020-21

Company Update19 May 2026

The Exchange has sought clarification from Suven Life Sciences Ltd on May 19, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.

BSE
Company Update19 May 2026

Clarification on Volume Movement Letter

Company Update14 May 2026

Newspaper Publication - Financial Results

Company Update14 May 2026

Monitoring Agency Report for the quarter ended March 31, 2026

Result13 May 2026

Outcome of the Board Meeting

Company Update13 May 2026

Grant of Stock options

Board Meeting13 May 2026

Outcome of Board Meeting of Suven Life Sciences Limited held on May 13, 2026

Company Update12 May 2026

Please find attached News Release of our company

Board Meeting06 May 2026

Suven Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2026 ,inter alia, to consider and approve Audited Financial Results ....

Company Update23 Apr 2026

Special window for Re-Lodgment of transfer requests of Physical shares

Company Update08 Apr 2026

Clarification on Price Movement

Company Update07 Apr 2026

The Exchange has sought clarification from Suven Life Sciences Ltd on April 7, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....

BSE
Company Update06 Apr 2026

Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st March, 2026

Insider Trading / SAST25 Mar 2026

Closure of Trading window

Insider Trading / SAST09 Mar 2026

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property & Equity Holdings Pvt Ltd & PACs

Others06 Mar 2026

ALLOTMENT OF 3,17,68,764 EQUITY SHARES OF THE COMPANY ON PREFERENTIAL BASIS

Company Update06 Mar 2026

Allotment of Securities

Company Update19 Feb 2026

Special window for Re-lodgment of transfer requests of physical securities

Company Update06 Feb 2026

Clarification on Price Movement

Company Update05 Feb 2026

The Exchange has sought clarification from Suven Life Sciences Ltd on February 5, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....

BSE
Company Update03 Feb 2026

Monitoring Agency Report for the quarter ended December 31, 2025

Company Update30 Jan 2026

Newspaper advt. - Unaudited financial results for the quarter and nine months ended 31st December, 2025

Result29 Jan 2026

Outcome of the Meeting of Board of Directors

Board Meeting29 Jan 2026

Outcome of the Board Meeting

Company Update29 Jan 2026

Allotment of 44,77,612 of Equity Shares of the Company on preferential basis upon conversion 44,77,612 fully paid warrants

Company Update29 Jan 2026

Resignation of Mr. Shrenik Soni, Company Secretary & Compliance Officer (KMP) of the Company

Annual Reports

15

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

Credit Ratings

6
crisilRating update
22 Apr 2020Report
crisilRating update
27 Jan 2020Report
careRating update
31 Dec 2019Report
crisilRating update
06 Nov 2019Report
crisilRating update
14 Oct 2019Report
careRating update
02 May 2019Report

Concalls

25

Jul 2021

31 Jul 2021

Feb 2020

29 Feb 2020

Nov 2019

30 Nov 2019

Aug 2019

31 Aug 2019

May 2019

31 May 2019

May 2019

31 May 2019

Feb 2019

28 Feb 2019

Feb 2019

28 Feb 2019

Feb 2019

28 Feb 2019

Nov 2018

30 Nov 2018

Nov 2018

30 Nov 2018

Aug 2018

31 Aug 2018

May 2018

31 May 2018

Jan 2018

31 Jan 2018

Dec 2017

31 Dec 2017

Nov 2017

30 Nov 2017

Aug 2017

31 Aug 2017

Jun 2017

30 Jun 2017

Jun 2017

30 Jun 2017

May 2017

31 May 2017

May 2017

31 May 2017

Jan 2017

31 Jan 2017

Nov 2016

30 Nov 2016

Aug 2016

31 Aug 2016

Feb 2016

29 Feb 2016

Held by ETFs

1 ETFs hold SUVEN · sorted by weight

#ETFWeight %
1

MOHEALTH

MOTILALAMC - MOHEALTH

0.14%

Held by Mutual Funds

3 schemes hold SUVEN · sorted by weight

#SchemeWeight %
1

Quant Small Cap Fund

Quant Mutual Fund

0.39%
2

Bandhan BSE Healthcare Index Fund

Bandhan Mutual Fund

0.13%
3

Motilal Oswal BSE 1000 Index Fund

Motilal Oswal Mutual Fund

0.01%